Source link : https://www.newshealth.biz/health-news/sglt2-hesitance-furosemides-indication-grows-legal-fight-over-entresto-generic/
From 2022 to 2023, uptake of SGLT2 inhibitors was low in patients with a class Ia recommendation. (Journal of the American College of Cardiology) In a phase IIa study, the oral controlled metabolic accelerator drug HU6 resulted in weight loss for patients with obesity-related heart failure with preserved ejection fraction, according to Rivus Pharmaceuticals. Plant […]
Author : News Health
Publish date : 2024-08-13 17:50:30
Copyright for syndicated content belongs to the linked Source.
Categories